Table 1.

Demographic characteristics of all the 5-year survivors alive at the time of the study (n=573) and for levels 1, 2 and 3 subgroups

Characteristic	Five-year survivors (n-573)		Level 1(n=86)		Level 2 (n=258)		Level 3 (n=229)
	n	Per cent	n	Per cent	n	Per cent	n	Per cent
Sex
Male	303	52.9	37	43	137	53.1	129	56.3
Female	270	47.1	49	57	121	46.9	100	43.7
Current age (years)
5–9	44	7.7	11	12.8	15	5.8	18	7.8
10–14	110	19.2	19	22.1	56	21.7	35	15.3
15–19	148	25.8	31	36.0	66	25.6	51	22.3
20–24	129	22.5	19	22.1	51	19.8	59	25.8
25–29	69	12.0	6	7.0	30	11.6	33	14.4
30–34	40	7.0	–	–	16	6.2	24	10.5
35–39	21	3.7	–	–	15	5.8	6	2.6
40–44	11	1.9	–	–	8	3.1	3	1.3
45–49	1	0.2	–	–	1	0.4	–	–
Median (range)	19.4	5.1–45.1	17.5	5.1–28.4	19.4	8.0–45.1	20.1	5.6–43.7
Age at diagnosis (years)
0–4	286	49.9	54	62.8	140	54.3	92	40.2
5–9	144	25.1	16	18.6	68	26.4	60	26.2
10–14	122	21.3	15	17.4	48	18.6	59	25.8
15–19	21	3.7	1	1.2	2	0.7	18	7.8
Median (range)	5.0	0–20.9	2.9	0–15.4	4.5	0–20.9	6.5	0–17.5
Time from diagnosis (years)
5–9	197	34.4	33	38.4	80	31.0	84	36.7
10–14	166	29.0	32	37.2	76	29.5	58	25.3
15–19	100	17.5	11	12.8	38	14.7	51	22.3
20–24	58	10.1	8	9.3	30	11.6	20	8.7
25–29	30	5.2	2	2.3	16	6.2	12	5.2
30–34	12	2.1	–	–	10	3.9	2	0.9
35–39	10	1.7	–	–	8	3.1	2	0.9
Median (range)	12.4	5.0–39.3	11.0	5.0–26.9	13.0	5.0–38.4	12.9	5.0–39.3
DFS (years)
0–4	36	6.3	1	1.2	20	7.7	15	6.5
5–9	198	34.5	34	39.5	82	31.8	82	35.8
10–14	160	27.9	31	36.0	67	26.0	62	27.1
15–19	84	14.7	10	11.6	34	13.2	40	17.5
20–24	57	9.9	8	9.3	31	12.0	18	7.9
25–29	19	3.4	2	2.4	8	3.1	9	3.9
30–34	17	3.0	–	–	15	5.8	2	0.9
35–39	2	0.3	–	–	1	0.4	1	0.4
Median (range)	11.3	0.5–38.3	10.9	4.4–26.9	11.6	1.9–36.4	11.6	0.5–38.3
Time since last seen in hospital-based late effects clinic (years)
0–2	328	57.2	31	36.0	143	55.4	154	67.2
3–4	75	13.1	16	18.6	36	13.9	23	10.1
5–7	78	13.6	20	23.3	40	15.5	18	7.9
8–10	28	5.0	6	7.0	10	3.9	12	5.2
>10	41	7.1	8	9.3	19	7.4	14	6.1
Unknown	23	4.0	5	5.8	10	3.9	8	3.5
Median (range)	2.3	0–13.1	4.5	0–12.7	2.2	0–12.7	1.8	0–13.1

DFS, disease free survival.